SG Americas Securities LLC Acquires 4,406 Shares of Nevro Corp. (NYSE:NVRO)

SG Americas Securities LLC increased its holdings in Nevro Corp. (NYSE:NVRO) by 34.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,126 shares of the medical equipment provider’s stock after purchasing an additional 4,406 shares during the quarter. SG Americas Securities LLC’s holdings in Nevro were worth $64,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of NVRO. Western Standard LLC bought a new stake in shares of Nevro in the third quarter worth about $5,473,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Nevro by 130.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,000,000 shares of the medical equipment provider’s stock valued at $5,590,000 after acquiring an additional 566,462 shares in the last quarter. Engaged Capital LLC boosted its position in Nevro by 29.5% during the 3rd quarter. Engaged Capital LLC now owns 2,442,956 shares of the medical equipment provider’s stock valued at $13,656,000 after acquiring an additional 557,000 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its position in Nevro by 50.8% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 732,717 shares of the medical equipment provider’s stock valued at $4,096,000 after acquiring an additional 246,979 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in Nevro by 27.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 929,348 shares of the medical equipment provider’s stock valued at $5,195,000 after acquiring an additional 200,885 shares in the last quarter. 95.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on the company. JMP Securities reaffirmed a “market perform” rating on shares of Nevro in a research report on Tuesday, November 12th. Truist Financial cut their price objective on Nevro from $7.00 to $4.70 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Citigroup cut their price objective on Nevro from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $7.00 price objective on shares of Nevro in a research report on Tuesday, November 12th. Finally, StockNews.com upgraded shares of Nevro from a “sell” rating to a “hold” rating in a report on Tuesday, November 19th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $6.43.

Nevro Price Performance

Shares of NYSE NVRO opened at $5.72 on Friday. Nevro Corp. has a twelve month low of $3.16 and a twelve month high of $17.63. The firm has a market cap of $214.14 million, a P/E ratio of -3.02 and a beta of 0.91. The company has a 50 day moving average of $4.39 and a 200 day moving average of $5.09. The company has a quick ratio of 3.76, a current ratio of 5.02 and a debt-to-equity ratio of 0.67.

Nevro (NYSE:NVRO) last announced its quarterly earnings data on Monday, November 11th. The medical equipment provider reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.40. Nevro had a negative net margin of 16.54% and a negative return on equity of 23.52%. The company had revenue of $96.60 million during the quarter, compared to analyst estimates of $93.09 million. During the same period in the previous year, the business earned ($0.65) EPS. The firm’s revenue for the quarter was down 7.0% on a year-over-year basis. As a group, research analysts expect that Nevro Corp. will post -2.43 EPS for the current fiscal year.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.